Page last updated: 2024-12-09

2-(4-methylanilino)-4-pyrido[3,2-e][1,3]thiazinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, **2-(4-methylanilino)-4-pyrido[3,2-e][1,3]thiazinone**, is a complex organic molecule with potential applications in medicinal chemistry and materials science. Here's a breakdown:

**Structure and Composition:**

* **2-(4-methylanilino):** This part indicates a 4-methylaniline group (aniline with a methyl group at the para position) attached to the thiazinone ring at position 2.
* **4-pyrido[3,2-e][1,3]thiazinone:** This refers to a thiazinone ring system fused with a pyridine ring. The pyrido part indicates that a pyridine ring is fused to the thiazinone ring, and the [3,2-e] specifies how the pyridine ring is attached.

**Potential Applications:**

* **Medicinal Chemistry:** This molecule might possess interesting pharmacological properties due to its unique structure. It could potentially act as:
* **Anti-inflammatory agent:** Thiazinone derivatives have been reported to have anti-inflammatory effects.
* **Antimicrobial agent:** The presence of the heterocyclic ring system could offer antimicrobial activity.
* **Anticancer agent:** Compounds with thiazinone rings have shown promising anticancer activity in some studies.
* **Materials Science:** This molecule could find application in:
* **Organic electronics:** Thiazinones are known for their potential as organic semiconductors and have been investigated for use in organic light-emitting diodes (OLEDs) and solar cells.

**Research Importance:**

The importance of this compound in research lies in its:

* **Novel Structure:** The combination of the thiazinone and pyridine rings creates a unique structure that might exhibit interesting properties.
* **Potential for Biological Activity:** The presence of functional groups like the aniline moiety suggests potential for biological activity.
* **Opportunities for Drug Development:** The study of this compound could lead to the discovery of new drugs with therapeutic benefits.
* **Material Science Applications:** Exploring its electronic properties could pave the way for new materials for organic electronics.

**Note:** It's important to remember that the exact properties and applications of this specific compound are still under investigation. Further research is needed to fully understand its potential.

Cross-References

ID SourceID
PubMed CID973891
CHEMBL ID1481930
CHEBI ID120750
SCHEMBL ID7099764

Synonyms (21)

Synonym
2-[(4-methylphenyl)amino]-4h-pyrido[3,2-e][1,3]thiazin-4-one
MLS000064990 ,
smr000078324
CHEMDIV2_001928
BAS 09531330 ,
STK335378
CHEBI:120750
2-(4-methylanilino)pyrido[3,2-e][1,3]thiazin-4-one
HMS1374H14
AKOS000585926
HMS2485P17
89374-39-0
CHEMBL1481930
2-(4-methylanilino)-4h-pyrido[3,2-e]-1,3-thiazin-4-one
SCHEMBL7099764
pyrido[3,2-e][1,3]thiazin-4-one, 2-p-tolylamino-
Q27208887
2-(4-methylanilino)-4-pyrido[3,2-e][1,3]thiazinone
DTXSID60359586
CCG-275116
2-(4-toluidino)-4h-pyrido[3,2-e][1,3]thiazin-4-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency11.99550.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency16.79580.004110.890331.5287AID504466; AID504467
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.16230.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency5.80480.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency2.51190.00022.621531.4954AID485297
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency12.78000.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]